Brian Park, PharmD

All articles by Brian Park, PharmD

Apabetalone Receives Breakthrough Therapy Designation for MACE Prevention

February 5, 2020

The FDA has granted Breakthrough Therapy designation to apabetalone (Resverlogix Corp) in combination with standard of care therapy, including high-intensity statins, for the secondary prevention of major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus and recent acute coronary syndrome.

Type 1 Diabetes

FDA Advisory Committee Votes Against Empagliflozin for Type 1 Diabetes

Brian Park, PharmD

November 14, 2019

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 against the approval of empagliflozin 2.5 mg as an adjunct to insulin for adults with type 1 diabetes.

Next post in Type 1 Diabetes

Brian Park, PharmD

All articles by Brian Park, PharmD

Apabetalone Receives Breakthrough Therapy Designation for MACE Prevention

FDA Advisory Committee Votes Against Empagliflozin for Type 1 Diabetes

Closed-Loop System Better Controls Blood Glucose Than Sensor-Augmented Insulin Pump